الفهرس 
Review of literatureOnly 14 pages are availabe for public view
 |  | from | 63 |  |  |
| | | from | 63 | | |
Abstract
Corneal NV can occur as a consequence of anterior segment inflammation, injury and ischemia. This unwanted pathological response can cause visual impairment or other conditions such as corneal edema, corneal scarring, lipid deposition, increased risk of graft rejection after corneal transplantation, and bleeding during corneal flap preparation in laser in situ keratomileusis (LASIK) surgery.
Several studies have shown that anti-VEGF agents can inhibit corneal NV. One such inhibitor is bevacizumab, a humanized murine monoclonal antibody against all VEGF isoforms.
In this study, Bevacizumab was used topically as eye drops with a concentration of 0.5 mg/ml. Total thirty patients were included in this study. All were diagnosed with corneal NV. Careful history was taken from all patients and they underwent ophthalmological examination including BCVA, slit lamp biomicroscopy examination and color photos of the anterior segment.
They received bevacizumab topical eye drops four times daily for two weeks. Patients were followed up at the end of the first and second week after treatment. At the last visit, it was found that 17 eyes showed regression of the corneal neovessels and 9 eyes showed improvement of the BCVA and only 4 eyes showed decrease in the corneal opacity. No complications were reported in this study.